Skip to main content Skip to search Skip to main navigation
News: Medical Devices

MedTech: Call for Structural Reform of MDR and IVDR

MedTech Europe, along with 34 national associations, published an open letter to EU Health Commissioner Stella Kyriakides on 14 September 2023.

In the 3-page letter, the stakeholders, on behalf of the MedTech industry, point out that an urgent and comprehensive reform is necessary to address the challenges created by the Medical Devices Regulation (MDR (EU) 2017/745) and the In Vitro Diagnostic Medical Devices Regulation (IVDR (EU) 2017/746).

One of the original objectives of the regulations, to establish a stable and transparent regulatory framework that ensures a high level of safety and health while supporting innovation, has not been implemented sufficiently after more than six years, they argue. What is problematic is that both medical technology innovations already on the market and future innovations have a hard time reaching European patients and healthcare systems.

According to the trade groups, structural problems in the legal framework of the MDR and IVDR are to blame. They are therefore calling for comprehensive changes in the regulations to minimise the lack of agility and innovation.

Trade associations are calling for three main improvements:

  • A more efficient and fit-for-purpose CE marking system,
  • a system that supports innovation in medical technology, and
  • a single structure to oversee and manage the regulatory system.

In addition to the demands, the open letter also proposes solutions and measures to improve the current situation.

Stella Kyriakides was offered the cooperation and support of the industry:"We stand ready to work together with you and the European Commission services to address this pressing situation and work toward the comprehensive structural reform necessary to achieve the stated objectives of the regulations.."


Source:

MedTech Europe: Open Letter

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next